Showing results (61-70 of 67) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.The Journal of Allergy and Clinical Immunology|July 28, 2023
Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumabFeiyang Ma, Mehrnaz Gharaee-Kermani, Lam C Tsoi, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.The New England Journal of Medicine|October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo NodularisShawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.Pageof 7